

## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mr. BHAVYAM

**AGE/ GENDER** : 31 YRS/MALE **PATIENT ID** : 1688061

**COLLECTED BY** : 122412020019 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 12:17 PM BARCODE NO. : 12505959 **COLLECTION DATE** : 02/Dec/2024 12:26PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 01:12PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

# **HAEMATOLOGY COMPLETE BLOOD COUNT (CBC)**

### **RED BLOOD CELLS (RBCS) COUNT AND INDICES**

HAEMOGLOBIN (HB) by CALORIMETRIC	14.5	gm/dL	12.0 - 17.0
RED BLOOD CELL (RBC) COUNT by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	4.57	Millions/cmm	3.50 - 5.00
PACKED CELL VOLUME (PCV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	41.9	%	40.0 - 54.0
MEAN CORPUSCULAR VOLUME (MCV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	91.8	fL	80.0 - 100.0
MEAN CORPUSCULAR HAEMOGLOBIN (MCH) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	31.7	pg	27.0 - 34.0
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	34.5	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WIDTH (RDW-CV) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	12.8	%	11.00 - 16.00
RED CELL DISTRIBUTION WIDTH (RDW-SD) by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER	43.8	fL	35.0 - 56.0
MENTZERS INDEX by CALCULATED	20.09	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX by CALCULATED	25.69	RATIO	BETA THALASSEMIA TRAIT:<= 65.0 IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CELLS (WBCS)			
TOTAL LEUCOCYTE COUNT (TLC) by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	7560	/cmm	4000 - 11000
DIFFERENTIAL LEUCOCYTE COUNT (DLC)			
NEUTROPHILS by Flow cytometry by SF cube & microscopy	50	%	50 - 70



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. BHAVYAM

**AGE/ GENDER** : 31 YRS/MALE **PATIENT ID** : 1688061

**COLLECTED BY** REG. NO./LAB NO. : 122412020019

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 12:17 PM BARCODE NO. : 12505959 **COLLECTION DATE** : 02/Dec/2024 12:26PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 01:12PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval			
LYMPHOCYTES by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	42 <sup>H</sup>	%	20 - 40			
EOSINOPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	2	%	1 - 6			
MONOCYTES by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	6	%	2 - 12			
BASOPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	%	0 - 1			
ABSOLUTE LEUKOCYTES (WBC) COUNT						
ABSOLUTE NEUTROPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	3780	/cmm	2000 - 7500			
ABSOLUTE LYMPHOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	3175	/cmm	800 - 4900			
ABSOLUTE EOSINOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	151	/cmm	40 - 440			
ABSOLUTE MONOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	454	/cmm	80 - 880			
ABSOLUTE BASOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/cmm	0 - 110			
PLATELETS AND OTHER PLATELET PREDICTIVE MARKERS.						
PLATELET COUNT (PLT) by hydro dynamic focusing, electrical impedence	297000	/cmm	150000 - 450000			
PLATELETCRIT (PCT) by hydro dynamic focusing, electrical impedence	0.3	%	0.10 - 0.36			
MEAN PLATELET VOLUME (MPV) by hydro dynamic focusing, electrical impedence	10	fL	6.50 - 12.0			
PLATELET LARGE CELL COUNT (P-LCC) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	82000	/cmm	30000 - 90000			
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	27.5	%	11.0 - 45.0			
PLATELET DISTRIBUTION WIDTH (PDW) by hydro dynamic focusing, electrical impedence NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD	16.1	%	15.0 - 17.0			



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS, MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



## A PIONEER DIAGNOSTIC CENTRE

: 02/Dec/2024 01:21PM

**NAME** : Mr. BHAVYAM

: 1688061 AGE/ GENDER : 31 YRS/MALE **PATIENT ID** 

**COLLECTED BY** REG. NO./LAB NO. : 122412020019

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 12:17 PM BARCODE NO. **COLLECTION DATE** : 02/Dec/2024 12:26PM : 12505959

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

**Value** Unit **Test Name Biological Reference interval** 

### **ERYTHROCYTE SEDIMENTATION RATE (ESR)**

ERYTHROCYTE SEDIMENTATION RATE (ESR)

mm/1st hr 0 - 20

REPORTING DATE

by RED CELL AGGREGATION BY CAPILLARY PHOTOMETRY

#### INTERPRETATION:

CLIENT CODE.

- 1. ESR is a non-specific test because an elevated result often indicates the presence of inflammation associated with infection, cancer and auto-immune disease, but does not tell the health practitioner exactly where the inflammation is in the body or what is causing it.
- 2. An ESR can be affected by other conditions besides inflammation. For this reason, the ESR is typically used in conjunction with other test such as C-reactive protein
- 3. This test may also be used to monitor disease activity and response to therapy in both of the above diseases as well as some others, such as systemic lupus erythematosus

#### CONDITION WITH LOW ESR

A low ESR can be seen with conditions that inhibit the normal sedimentation of red blood cells, such as a high red blood cell count (polycythaemia), significantly high white blood cell count (leucocytosis), and some protein abnormalities. Some changes in red cell shape (such as sickle cells in sickle cell anaemia) also lower the ESR.

### NOTE:

- 1. ESR and C reactive protein (C-RP) are both markers of inflammation.
- 2. Generally, ESR does not change as rapidly as does CRP, either at the start of inflammation or as it resolves.
   3. CRP is not affected by as many other factors as is ESR, making it a better marker of inflammation.
   4. If the ESR is elevated, it is typically a result of two types of proteins, globulins or fibringen.
   5. Women tend to average mathyldone and entraceptives professional processing mathyldone and with the opposition of the oppositio

- 6. Drugs such as dextran, methyldopa, oral contraceptives, penicillamine procainamide, theophylline, and vitamin A can increase ESR, while aspirin, cortisone, and quinine may decrease it



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. BHAVYAM

AGE/ GENDER : 31 YRS/MALE **PATIENT ID** : 1688061

**COLLECTED BY** REG. NO./LAB NO. : 122412020019

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 01:35 PM BARCODE NO. **COLLECTION DATE** : 02/Dec/2024 02:44PM : 12505959 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 02:58PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Test Name Biological Reference interval** 

### CLINICAL CHEMISTRY/BIOCHEMISTRY

**LIPID PROFILE: BASIC** 

CHOLESTEROL TOTAL: SERUM OPTIMAL: < 200.0  $203.92^{H}$ mg/dL

by CHOLESTEROL OXIDASE PAP BORDERLINE HIGH: 200.0 -

239.0

HIGH CHOLESTEROL: > OR =

240.0

TRIGLYCERIDES: SERUM 174.54<sup>H</sup> OPTIMAL: < 150.0 mg/dL by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC) BORDERLINE HIGH: 150.0 -

199.0

HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM LOW HDL: < 30.0 34.44 mg/dL

by SELECTIVE INHIBITION BORDERLINE HIGH HDL: 30.0 -

60.0  $HIGH\ HDL: > OR = 60.0$ 

LDL CHOLESTEROL: SERUM OPTIMAL: < 100.0 134.57<sup>H</sup> mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 -

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM 169.48<sup>H</sup> mg/dL OPTIMAL: < 130.0 by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 -

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

mg/dL VLDL CHOLESTEROL: SERUM 34.91 0.00 - 45.00

by CALCULATED. SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM 582.38 350.00 - 700.00 mg/dL

CHOLESTEROL/HDL RATIO: SERUM 5.92H RATIO LOW RISK: 3.30 - 4.40 by CALCULATED, SPECTROPHOTOMETRY

AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



by CALCULATED, SPECTROPHOTOMETRY





## A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mr. BHAVYAM

AGE/ GENDER : 31 YRS/MALE **PATIENT ID** : 1688061

**COLLECTED BY** REG. NO./LAB NO. : 122412020019

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 01:35 PM BARCODE NO. **COLLECTION DATE** : 02/Dec/2024 02:44PM : 12505959 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 02:58PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	<b>Biological Reference interval</b>
			MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.91 <sup>H</sup>	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	5.07 <sup>H</sup>	RATIO	3.00 - 5.00

**INTERPRETATION:** 

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





## A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mr. BHAVYAM

AGE/ GENDER : 31 YRS/MALE **PATIENT ID** : 1688061

**COLLECTED BY** REG. NO./LAB NO. : 122412020019

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 12:17 PM BARCODE NO. : 12505959 **COLLECTION DATE** : 02/Dec/2024 12:26PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 01:12PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name** 

# IMMUNOPATHOLOGY/SEROLOGY HEPATITIS B SURFACE ANTIGEN (HBsAg) SCREENING

HEPATITIS B SURFACE ANTIGEN (HBsAg) RESULT

NON - REACTIVE

by IMMUNOCHROMATOGRAPHY

#### INTERPRETATION:-

1.HBsAG is the first serological marker of HBV infection to appear in the blood (approximately 30-60 days after infection and prior to the onset of clinical disease). It is also the last viral protein to disappear from blood and usually disappears by three months after infection in self limiting acute Hepatitis B viral infection.

2. Persistence of HBsAg in blood for more than six months implies chronic infection. It is the most common marker used for diagnosis of an acute Hepatitis B infection but has very limited role in assessing patients suffering from chronic hepatitis.

### **FALSE NEGATIVE RESULT SEEN IN:**

- 1. Window period.
- 2.Infection with HBsAg mutant strains
- 3. Hepatitis B Surface antigen (HBsAg) is the earliest indicator of HBV infection. Usually it appears in 27 41 days (as early as 14 days).
- 4. Appears 7 26 days before biochemical abnormalities. Peaks as ALT rises. Persists during the acute illness. Usually disappears 12-20 weeks after the onset of symptoms / laboratory abnormalities in 90% of cases.
- 5.Is the most reliable serologic marker of HBV infection. Persistence > 6 months defines carrier state. May also be found in chronic infection. Hepatitis B vaccination does not cause a positive HBsAq. Titers are not of clinical value.

#### NOTE:-

- 1.All reactive HBsAG Should be reconfirmed with neutralization test(HBsAg confirmatory test).
- 2.Anti HAV IgM appears at the same time as symptoms in > 99% of cases, peaks within the first month, becomes nondetectable in 12 months (usually 6 months). Presence confirms diagnosis of recent acute infection.

\*\*\* End Of Report \*\*\*



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

